Patents by Inventor Joseph Eiden, Jr.

Joseph Eiden, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8333980
    Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: December 18, 2012
    Assignee: Dynavax Technologies Corporation
    Inventors: Gary Van Nest, Stephen F. Tuck, Joseph Eiden, Jr.
  • Publication number: 20100183666
    Abstract: The invention provides methods for the treatment of papillomavirus infections. A polynucleotide comprising an immunostimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection.
    Type: Application
    Filed: February 5, 2010
    Publication date: July 22, 2010
    Applicant: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: GARY VAN NEST, JOSEPH EIDEN, JR.
  • Publication number: 20090148479
    Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.
    Type: Application
    Filed: November 13, 2008
    Publication date: June 11, 2009
    Inventors: Gary Van Nest, Stephen Tuck, Joseph Eiden, JR.
  • Patent number: 7479285
    Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: January 20, 2009
    Assignee: Dynavax Technologies Corporation
    Inventors: Gary Van Nest, Stephen Tuck, Joseph Eiden, Jr.